This Quantum Computing Leader Is up 3,310% Since 2023. Is It Too Late to Buy?

D-Wave Quantum reported fiscal 2025 revenue growth of 179% to $24.6 million and a first-quarter bookings record of $33.4 million, but revenue fell 81% year over year in Q1 2026 to $2.9 million. Losses remain substantial at $355.1 million in 2025 versus IonQ's $130 million in revenue, highlighting weaker commercial traction despite a $550 million Quantum Circuits acquisition and a defense collaboration. The stock already trades at about 249x sales, suggesting much of the growth optimism is priced in.

Analysis

QBTS is transitioning from a pure sentiment trade into a capital-allocation story, but the market is still pricing it like a winner-take-most platform despite evidence that monetization is uneven. The key second-order effect is that a record bookings print can temporarily mask weak current revenue conversion, which often leads to multiple compression once investors stop rewarding pipeline headlines and start focusing on cash burn and dilution. The market is likely underestimating how expensive it will be to sustain this pace of commercial expansion if customer adoption remains lumpy.

The acquisition of a second compute architecture is strategically interesting, but it also raises integration and product-market-fit risk: dual-platform breadth can widen the addressable market, yet it can just as easily increase R&D intensity and slow the path to gross-margin improvement. Defense collaboration is a better signal than enterprise hype because it creates a longer-duration procurement funnel and potential follow-on contracts, but that revenue will likely arrive in small, politically sensitive tranches over many quarters rather than as a near-term step function.

IONQ remains the cleaner relative beneficiary on any "quantum is real" re-rating because scale in revenue gives it better credibility with large customers, channel partners, and financing counterparties. The contrarian angle is that QBTS may actually be the more interesting tactical short if the stock is still being valued on narrative acceleration: once the market shifts from TAM to execution, the gap between bookings and recognized revenue becomes the first thing investors punish. NVDA and INTC are only marginally exposed here, but any broad quantum enthusiasm can support a higher-duration, infrastructure-adjacent bid; that support is likely more sentiment-driven than fundamentals-driven.

Near term, the catalyst stack is binary and time-sensitive: the next 1-2 quarters will determine whether bookings convert or whether the company needs to finance growth at a punitive valuation. The biggest tail risk is not technological failure but dilution combined with a downgrade in credibility if backlog does not translate into repeatable revenue. If that happens, the stock can rerate sharply lower even without an operational collapse, simply because expectations are now too high for a pre-profit company with weak current earnings power.

Key Decisions for Investors

• Short QBTS into strength on a 1-3 month horizon; use rallies driven by bookings headlines to fade valuation expansion, with a stop above the most recent post-announcement breakout if momentum persists.
• Pair trade: long IONQ / short QBTS for 3-6 months to express preference for the better-commercialized leader; thesis is that scale should outperform narrative once investors refocus on revenue quality.
• Buy QBTS put spreads 2-4 months out to capture a potential reset in multiple as the market digests dilution and revenue lumpiness; structure for defined risk because squeeze risk remains high.
• Hold a small tracking position only if already long quantum exposure, but cap it at a token weight; the risk/reward is unfavorable at current valuation unless bookings translate into consecutive revenue inflections within two quarters.
• Avoid initiating new long exposure in NVDA/INTC purely on quantum enthusiasm; if anything, use any sector-wide strength to trim, since the article supports sentiment spillover more than material fundamental upside.